The takeaway
An early study of an amylin-based medicine found weight loss in selected follow-up groups. Those groups were smaller than the original trial population, which matters when interpreting one-year results.
What was the study?
In 2008, researchers reported a trial in 411 adults with obesity without diabetes; 408 received study medication. Everyone received lifestyle intervention. The four-month randomized, double-blind phase was followed by an optional eight-month single-blind extension of assigned treatment.
Who was evaluable?
The 270 participants evaluable at four months were eligible for the extension; 209 entered it, and 146 were evaluable at one year. Evaluable participants met study criteria for duration, medication and compliance. At one year, this included remaining through month 12 or receiving medication for at least 330 days, without restricted concomitant medication and with acceptable compliance. Evaluable is not the same as everyone who completed treatment or the only one-year analysis.
Evaluable participants met the study’s analysis criteria
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Randomized | 411 |
| Received medication | 408 |
| Evaluable at four months | 270 |
| Entered extension | 209 |
| Evaluable at one year | 146 |
What did researchers observe?
Most active regimens maintained or extended weight reduction, except the lowest twice-daily arm. Excluding that arm, one-year evaluable mean losses were 6.0%–7.9% from initial baseline versus 1.1% with placebo. In the separate 209-person extension intention-to-treat analysis, losses were 5.5%–6.6% versus 2.2% with placebo. The main-phase intention-to-treat analysis included 408 people. Missing measurements were carried forward separately within each phase; the extension analysis did not restore the original population.
The trade-offs
Initially, nausea affected 9%–29% across active arms versus 2% with placebo, and 12 active-treatment participants withdrew because of nausea. Attrition, voluntary extension entry and eligibility criteria limit how well these selected results generalize. Counts alone do not show why everyone left or which treatment is safer.
Why read this now?
This is a chapter in amylin-based obesity research, not proof of an approved weight-management use. Four authors were affiliated with Amylin Pharmaceuticals. The displayed US SYMLIN label, revised December 2019, concerns diabetes treatment with mealtime insulin and includes a boxed warning about severe hypoglycemia with insulin.